CVS Health to Roll Out New Drug Pricing Model
Joe Raedle/Getty

CVS Health Corp. (CVS)  said on Wednesday that its prescription benefit management subsidiary, CVS Caremark, will roll out a new pricing model that it said will offer greater "drug cost predictability and pricing simplicity."

According to the company, the new model will allow CVS to pass through 100% of drug rebates to its health plan clients. CVS, which completed its $69 billion acquisition of health insurer Aetna Inc. last week, said it would begin rolling out the new model starting in 2019.

So-called PBMs and the rebates they receive from drug companies have more recently come under scrutiny as well as criticism from both policymakers and the pubic, who have been calling for greater transparency related to their financial arrangements.

CVS shares ended the day Tuesday down 61 cents at $78.91 on the New York Stock Exchange. U.S. markets were closed Wednesday to commemorate the death of former U.S. President George H.W. Bush.

More from Investing

Johnson & Johnson Breaks Down Sharply on the Charts So Take Action

Johnson & Johnson Breaks Down Sharply on the Charts So Take Action

Jim Cramer: I Can't Tell You to Buy This Market

Jim Cramer: I Can't Tell You to Buy This Market

Innovative Industrial Properties Still Pointed Up, but Don't Get Too Confident

Innovative Industrial Properties Still Pointed Up, but Don't Get Too Confident

Johnson & Johnson Shares Plunge After Report It Knew of Asbestos in Baby Powder

Johnson & Johnson Shares Plunge After Report It Knew of Asbestos in Baby Powder

Starbucks Drops After Trimming Long-Term Earnings Growth Aim

Starbucks Drops After Trimming Long-Term Earnings Growth Aim